From research bench to global market: leveraging Weizmannia coagulans BC99 for real-world applications

The shift of probiotics from supplements to daily foods has exposed a critical divide between clinically studied strains and those viable in real-world production. While many research-backed strains cannot withstand industrial processing, scalable strains often lack clinical evidence. To bridge this gap, a probiotic must be both scientifically validated and functionally resilient for mass-market applications.